EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Microplastics matter: practical implications of the EU REACH restriction for the pharmaceutical industry

Pauline Henrica Maria Janssen, Willem Antoon Rijpkema, Lorina Bisharat, Marlijn Orbons, Maarten Jaspers, Bastiaan Hendricus Jozef Dickhoff

Frontiers in Drug Delivery · 04.06.2026 · 6

DOI: 10.3389/fddev.2026.1854462 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Drug Delivery, online erschienen am 04.06.2026. Verfasst von Pauline Henrica Maria Janssen und 5 weiteren Autor:innen. Beteiligte Einrichtung: DFE Pharma GmbH & Co. KG, Innovation and Technical Services, Goch, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synthetic polymer microparticles (SPMs), commonly referred to as microplastics, are subject to increasing restrictions due to their environmental persistence and uncertainty about potential human health effects. These substances are regulated under Regulation (EC) No 1907/2006 (REACH). Commission Regulation (EU) 2023/2055 amends REACH by introducing a restriction on SPMs in Annex XVII, including phased information and reporting obligations for in-scope uses. Although medicinal products are derogated from the market ban, these obligations have practical implications for pharmaceutical supply chains. Medicinal products containing SPMs are subject to specific reporting obligations under the REACH regulation. These obligations apply when the excipients meet the SPM definition and cannot be excluded based on criteria such as being naturally occurring, or due to their solubility or demonstrated degradability. This paper presents an operational decision-making framework that interprets the EU REACH restriction on SPM for pharmaceutical excipients and drug-delivery systems. The framework integrates regulatory definitions with testing strategies, supplier qualification processes, and downstream compliance workflows. An industry case example illustrates a combined approach using portfolio screening and biodegradation testing. This can generate evidence to support compliance decisions while preserving formulation performance.

Schlagwörter

Stichwörter der Autor:innen

biodegradabilitymedicinal product manufacturingmicroplasticspolymeric excipientsreachregulatory sciencesustainabilitysynthetic polymer microparticles

Autor:innen und Institutionen

  • DFE Pharma GmbH & Co. KG, Innovation and Technical Services, Goch, Germany.

Zitieren

APA

Janssen, P. H. M., Rijpkema, W. A., Bisharat, L., Orbons, M., Jaspers, M., & Dickhoff, B. H. J. (2026). Microplastics matter: practical implications of the EU REACH restriction for the pharmaceutical industry. Frontiers in Drug Delivery, 6. https://doi.org/10.3389/fddev.2026.1854462

Vancouver

Janssen PHM, Rijpkema WA, Bisharat L, Orbons M, Jaspers M, Dickhoff BHJ. Microplastics matter: practical implications of the EU REACH restriction for the pharmaceutical industry. Frontiers in Drug Delivery. 2026;6. doi:10.3389/fddev.2026.1854462

BibTeX
@article{Janssen2026,
  author = {Janssen, Pauline Henrica Maria and Rijpkema, Willem Antoon and Bisharat, Lorina and Orbons, Marlijn and Jaspers, Maarten and Dickhoff, Bastiaan Hendricus Jozef},
  title = {Microplastics matter: practical implications of the EU REACH restriction for the pharmaceutical industry},
  journal = {Frontiers in Drug Delivery},
  year = {2026},
  volume = {6},
  doi = {10.3389/fddev.2026.1854462}
}
Kostenlos starten →